Format

Send to

Choose Destination
Drug Des Devel Ther. 2015 Aug 5;9:4303-18. doi: 10.2147/DDDT.S86105. eCollection 2015.

The role of taxanes in triple-negative breast cancer: literature review.

Author information

1
Medical Oncology, University of Trieste, Trieste, Italy.
2
Breast Medical Oncology Unit, National Cancer Institute, Fondazione G. Pascale, Napoli, Italy.

Abstract

Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor.

KEYWORDS:

bevacizumab; docetaxel; nab-paclitaxel; paclitaxel

PMID:
26273192
PMCID:
PMC4532347
DOI:
10.2147/DDDT.S86105
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center